Esperion Therapeutics (ESPR) Tops Q3 EPS by 5c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.77), $0.05 better than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Jefferies Starts China Oilfield Services (A-Shares) (601808:CH) at Buy
• JPMorgan Downgrades Shenzhen Inovance Tech (300124:CH) to Neutral